{"symbol":"REGN","fiscalQuarter":"Q4-2017","reportDate":"2018-02-08","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2017","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 3.58%","keyNumbers":[{"metric":"EPS","actual":"$5.23","expected":"N/A","surprise":"+17.08%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite not providing revenue figures.","They highlighted ongoing investments in research and development as a priority."],"summary":"Overall, management conveyed a positive outlook on earnings performance while emphasizing their commitment to innovation. However, the lack of revenue guidance left some investors uncertain."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a strong EPS performance, beating expectations by over 17%. However, the stock fell by 3.58% in reaction, likely due to the absence of revenue figures and guidance, which may have raised concerns among investors about future growth prospects.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2017 earnings: EPS beat by 17.08%. Stock down 3.58%. Full breakdown."}}